Fig. 2From: Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept studyCorrelation between adjusted mean differences (+/− standard error) from placebo in amyloid PET and clinical efficacy endpoints (A CDR-SB; B ADCOMS; C ADAS-Cog) at 18 monthsBack to article page